Patent · US Active

Method of immunization for reducing toxic damaged caused by oligomeric form of the amyloid-beta protein with stable amyloid beta monomers and oligomers

US10023622B2 · kind B2 · utility

0Cited by

1References

9Claims

0Family size

Assignee

ALZINOVA AB · SE

Inventors

Torleif Härd · Uppsala, SE
Anders Sandberg · Blombacka, SE

Key dates

Filing date	May 19, 2017
Grant date	Jul 17, 2018
Priority date	—
Expiry date	May 19, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.